On November 5, 2020 Seagen Inc. (Nasdaq:SGEN) reported multiple ADCETRIS (brentuximab vedotin) data presentations at the upcoming 62nd American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, taking place virtually December 5-8, 2020 (Press release, Seagen, NOV 5, 2020, View Source [SID1234570001]). Data presentations will include five-year updates from the phase 3 ECHELON-1 and ECHELON-2 clinical trials evaluating ADCETRIS plus a chemotherapy combination regimen in frontline advanced stage Hodgkin lymphoma (HL) or frontline peripheral T-cell lymphoma (PTCL). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL and expressed on the surface of several types of PTCL. ADCETRIS is being evaluated globally in more than 70 corporate- and investigator-sponsored clinical trials across multiple settings in lymphoma and other indications.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"At this year’s ASH (Free ASH Whitepaper) meeting, ADCETRIS will be featured in 18 data presentations, including five-year analyses from the ECHELON-1 and ECHELON-2 phase 3 frontline trials," said Roger Dansey, M.D., Chief Medical Officer at Seagen. "Reaching five-years without disease recurrence represents a significant clinical milestone for patients, as they may be considered disease-free at this time point. The five-year data presentations from our phase 3 ECHELON-1 and ECHELON-2 trials demonstrate ADCETRIS plus chemotherapy resulted in superior clinical activity and durable benefit when compared to outcomes with a standard chemotherapy regimen. We will also present additional analyses from trials evaluating ADCETRIS in combination with other therapies, with the goal of identifying potential new treatment strategies that improve outcomes for patients."
Details of Seagen Presentations at ASH (Free ASH Whitepaper):
Abstract Title
Abstract #
Presentation
Type / Date
Presenter
Company-Sponsored Trials
Frontline Brentuximab Vedotin as Monotherapy or in Combination for Older Hodgkin Lymphoma Patients
#471
Oral presentation / Sunday, Dec. 6 at 2:15 p.m. PT
C. Yasenchak
Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin lymphoma: 5-year Update of the ECHELON-1 Study
#2973
Poster presentation / Monday, Dec. 7, 7:00 a.m. – 3:30 p.m. PT
D. Straus
The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-positive Peripheral T-cell Lymphoma
#1150
Poster presentation / Saturday, Dec. 5, 7:00 a.m. – 3:30 p.m. PT
S. Horwitz
Economic Assessment of Diagnostic Revision in Peripheral T-cell Lymphoma
#1606
Poster presentation / Saturday, Dec. 5, 7:00 a.m. – 3:30 p.m. PT
N. Liu
Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Mediastinal Gray Zone Lymphoma: Primary Efficacy and Safety Analysis of the Phase 2 CheckMate 436 Study
#2045
Poster presentation / Sunday, Dec. 6, 7:00 a.m. – 3:30 p.m. PT
A. Santoro
Real-World Characteristics of Patients with Classical Hodgkin Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching
#2499
Poster presentation / Sunday, Dec. 6, 7:00 a.m. – 3:30 p.m. PT
T. Phillips
Real-World Adherence to National Comprehensive Cancer Network (NCCN) Guidelines Regarding the Usage of PET/CT and Reported Deauville Scores in Advanced Stage Classical Hodgkin Lymphoma: A Community Oncology Practice Perspective
#2033
Poster presentation / Sunday, Dec. 6, 7:00 a.m. – 3:30 p.m. PT
C. Yasenchak
SGN-CD30C, an Investigational CD30-Directed Camptothecin Antibody-Drug Conjugate (ADC), Shows Strong Anti Tumor Activity and Superior Tolerability in Preclinical Studies
#2089
Poster presentation / Sunday, Dec. 6, 7:00 a.m. – 3:30 p.m. PT
M. Ryan
Real-World Characteristics of Patients with Peripheral T-Cell Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching
#3418
Poster presentation / Monday, Dec. 7, 7:00 a.m. – 3:30 p.m. PT
J. Burke
Nodal Peripheral T-Cell Lymphoma with T Follicular-Helper Phenotype: A Different Entity? Results of the Spanish Retrospective Real-T Study
#2972
Poster presentation / Monday, Dec. 7, 7:00 a.m. – 3:30 p.m. PT
AM. Garcia-Sancho
Results from the International, Multi-Center, Retrospective B-Holistic Study: Describing Treatment Pathways and Outcomes for Classical Hodgkin Lymphoma
#2979
Poster presentation / Monday, Dec. 7, 7:00 a.m. – 3:30 p.m. PT
B. Ferhanoglu
Investigator-Sponsored Trials
Increased Tumor Specific Cytotoxic T Cell Responses and Reversion to a Favorable Cytokine Profile after Treatment in Patients with Newly Diagnosed High Risk Hodgkin Lymphoma Treated on Children’s Oncology Group Trial- AHOD1331
#595
Oral presentation / Monday, Dec. 7 at 9:15 a.m. PT
H. Dave
Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a LYSA Multicenter, Phase II Study. "The TOTAL Trial"
#1161
Poster presentation / Saturday, Dec. 5, 7:00 a.m. – 3:30 p.m. PT
O. Tournilhac
A Pilot Study of Brentuximab Vedotin, Rituximab and Dose Attenuated CHP in Patients 75 Years and Older with Diffuse Large B-Cell Lymphoma
#2102
Poster presentation / Sunday, Dec. 6, 7:00 a.m. – 3:30 p.m. PT
P. Reagan
Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Is Highly Active for Second Line Treatment in Relapsed/Refractory Classical Hodgkin Lymphoma: Final Results of a Phase I/II Study
#2964
Poster presentation / Monday, Dec. 7, 7:00 a.m. – 3:30 p.m. PT
R. Lynch
A Phase I Trial Assessing the Feasibility of Romidepsin Combined with Brentuximab Vedotin for Patients Requiring Systemic Therapy for Cutaneous T-Cell Lymphoma
#2970
Poster presentation / Monday, Dec. 7, 7:00 a.m. – 3:30 p.m. PT
S. Barta
Trials-in-Progress
Trial-in-Progress: Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
#2112
Poster presentation / Sunday, Dec. 6, 7:00 a.m. – 3:30 p.m. PT
N. Bartlett
A Phase 1 Study of Sea-CD70 in Myeloid Malignancies
#2874
Poster presentation / Monday, Dec. 7, 7:00 a.m. – 3:30 p.m. PT
A. Aribi
Trial-in-Progress: Frontline Brentuximab Vedotin and CHP (A+CHP) in Patients with Peripheral T-Cell Lymphoma with Less Than 10% CD30 Expression
#2976
Poster presentation / Monday, Dec. 7, 7:00 a.m. – 3:30 p.m. PT
D. Jagadeesh